MAYO CLINIC HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $100.7M
- Transactions
- 8,928
- Companies
- 40
- Average per transaction
- $11,284
Who reported the payments
| Bristol Myers Squibb | $11,047,570 |
| Pfizer | $6,786,627 |
| E.r. Squibb & Sons, L.L.C. | $6,553,146 |
| Merck | $4,903,479 |
| Genentech, Inc. | $4,716,780 |
| AstraZeneca | $4,706,204 |
| AbbVie | $3,978,935 |
| Novartis | $3,877,114 |
| Boehringer Ingelheim | $3,247,948 |
| Incyte Corporation | $3,138,198 |
| Janssen Research & Development, LLC | $3,121,845 |
| Seagen Inc. | $2,410,577 |
| Kyowa Kirin, Inc. | $2,104,597 |
| Exelixis Inc. | $1,949,206 |
| Eli Lilly | $1,937,992 |
| Amgen | $1,825,824 |
| Sanofi US Services Inc. | $1,747,989 |
| Boston Scientific | $1,697,079 |
| Mirati Therapeutics, Inc. | $1,481,947 |
| Regeneron | $1,442,737 |
| CSL Behring | $1,419,712 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,318,722 |
| Olympus Corporation Of The Americas | $937,647 |
| Siemens Medical Solutions USA, Inc. | $891,204 |
| Clovis Oncology, Inc. | $882,070 |
| Deciphera Pharmaceuticals Inc. | $839,895 |
| Regeneron Healthcare Solutions, Inc. | $722,665 |
| Astellas Pharma Global Development | $607,805 |
| Jazz Pharmaceuticals Inc. | $561,477 |
| Stryker | $519,394 |
| Array Biopharma Inc | $504,603 |
| Blueprint Medicines Corporation | $470,092 |
| Gilead | $466,102 |
| EMD Serono, Inc. | $462,073 |
| Alkermes, Inc. | $444,610 |
| Agios Pharmaceuticals, Inc. | $398,519 |
| Beone Medicines USA, Inc. | $398,052 |
| Beigene, Ltd. | $376,339 |
| Alnylam Pharmaceuticals Inc. | $369,151 |
| Daiichi Sankyo Inc. | $363,807 |